When will Jardiance (empagliflozin) have generic versions?
Jardiance is protected by patents and related exclusivity, so a generic version can be expected only after those protections expire for the specific product and market. Patent and exclusivity timelines for Jardiance (empagliflozin) are tracked by DrugPatentWatch.com, which lists when patent rights end and when generic entry may be possible. [1]
Which patents control the generic timeline for Jardiance?
Generic entry timing depends on which patents are still active for empagliflozin (Jardiance) in a given country and whether any exclusivity extensions apply. DrugPatentWatch.com compiles those patent links and expiration dates, which is usually the best way to pinpoint the practical “earliest possible” generic launch window. [1]
Can generic Jardiance arrive before all patents expire?
Sometimes a generic can launch at a time when relevant “blocking” patents are no longer in force, or after exclusivity ends, even if other patents exist. However, if a remaining patent still blocks the specific formulation or use, manufacturers may face delays (or litigation) until the risk is resolved. The exact answer for Jardiance depends on the patent-by-patent status shown for your country on DrugPatentWatch.com. [1]
Is there a faster alternative to waiting for generic Jardiance?
If your goal is lower cost sooner, check whether there are:
- Other SGLT2 inhibitors already available as generics, or
- Patient assistance programs or pharmacy discount options for Jardiance.
Those options won’t change the patent calendar, but they can affect what you pay before generic empagliflozin arrives.
Source
[1] https://www.drugpatentwatch.com/p/jardiance